Sharemaestro company-news research for Cochlear Limited (COH), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
ASX
Australia
Provisional evidence
Company news sentiment
Latest COH news and sentiment
Cochlear Limited
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
6 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone36/100
→
Published 30-day score48/100
Latest source headline
Cochlear And 2 Other Australian Healthcare Stocks To Own
Simply Wall St · 30 Sep 2026 10:41
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
6 current stories are mapped specifically to COH.
What limits the score
Only 2 publishers currently contribute to the measured read.
The stories agree, but freshness-weighted evidence is only 0.142.
Confidence is 25/100, below the threshold for a firm score.
48/100
News scoreEarly balanced news score
25/100
Confidencethin evidence
100%/100
Company news6 company stories
97/100
Story agreement3/100 difference
News history
Daily score and story count over 30 days
10 Sep25 Sep09 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence3
0.142 after freshness weightingSource breadth40
2 independent publishersCompany relevance100
share tied directly to this companyFreshness18
recency-weighted evidenceAgreement97
how closely stories agreePublisher mix4
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks21 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
10 Apr07 Jul02 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
02 Oct 202647AUD 125.389999-11.9%
25 Sep 202650AUD 142.300003+7.3%
18 Sep 202650AUD 132.599991-0.2%
11 Sep 202651AUD 132.837662-6.0%
04 Sep 202649AUD 141.354172+4.9%
28 Aug 202648AUD 134.778641+0.5%
21 Aug 202648AUD 134.164658+0.4%
14 Aug 202651AUD 133.600006+7.0%
Provisional evidence
News subjects
What is shaping the score
Capital return532 stories · 33%
Market update502 stories · 33%
Regulatory and legal351 stories · 17%
Earnings571 stories · 17%
Source mix
Where the evidence comes from
Reuters351 stories · 17%
kalkine.com.au571 stories · 17%
GuruFocus.com551 stories · 17%
Simply Wall St501 stories · 17%
finance.yahoo.com501 stories · 17%
Simply Wall Street501 stories · 17%
Recurring subjects
Subjects appearing most often
Healthcare2Regulation1Implantable Devices1Hearing Technology1Growth1Fda Approval1Earnings Growth1Earnings1Dividends1Dividend Payments1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
21 Apr50 neutral09 Oct 05:25
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 09 Oct 05:25 | 48 | +1 | 24/100 (-9) | 6 (-2) | Provisional |
| 30 Sep 23:59 | 47 | +0 | 33/100 (-2) | 8 (0) | Provisional |
| 29 Sep 23:59 | 47 | -3 | 35/100 (+20) | 8 (+1) | Provisional |
| 28 Sep 23:59 | 50 | +0 | 15/100 (-2) | 7 (-2) | Provisional |
| 22 Sep 23:59 | 50 | +0 | 17/100 (-2) | 9 (0) | Provisional |
| 18 Sep 23:59 | 50 | -1 | 19/100 (-9) | 9 (-3) | Provisional |
| 11 Sep 23:59 | 51 | +1 | 28/100 (+2) | 12 (+1) | Provisional |
| 09 Sep 23:59 | 50 | +1 | 26/100 (+7) | 11 (-1) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 6 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Regulatory and legal1 story
98.1%0.0%
Earnings1 story
0.0%1.9%
Each side uses the same scale: 0–98.1% of the retained directional evidence.
Where the influence comes from
98.1%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Market updateNot used in direction
Cochlear And 2 Other Australian Healthcare Stocks To Own
Australian inflation accelerated to 4% in August, and interest rates now sit at a 15 year high of 4.6%. That mix is putting cost pressure on households while lifting the appeal of resilient sectors. Healthcare often holds up when budgets tighten because treatment is hard to postpone. This…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Australian inflation accelerated to 4% in August, and interest rates now sit at a 15 year high of 4.6%. That mix is putting cost pressure on households while lifting the appeal of resilient sectors. Healthcare often holds up when budgets tighten because treatment is hard to postpone. This article walks through three leading Australian healthcare stocks from a high quality screener that targets robust balance sheets and proven business models. The three stocks in focus below are a starting sample from the healthcare space. The full screen surfaced 9 more companies with similarly compelling stor
- Published
- 30 Sep 2026 10:41
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 3 consolidated
BiotechFda ApprovalHealthcare
35/100 tone
Regulatory and legal
Australia's Cochlear hit with shareholder lawsuit over 2026 earnings forecast
98.1% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
- Published
- 29 Sep 2026 22:46
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 51/100
- 30-day weight
- 98.1% of directional evidence · 9.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Cochlear Reaches More Than 1 Million Hours of Patient Experience Across Its Fully Implantable Hearing Technology Research Program
Global clinical studies advance Cochlear's fully implantable hearing technology US, European and Australian pivotal trial recruitment completed, and more than 100 people implanted across the full research program Program reflects Cochlear's evidence-led approach to developing breakthrough…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Global clinical studies advance Cochlear's fully implantable hearing technology US, European and Australian pivotal trial recruitment completed, and more than 100 people implanted across the full research program Program reflects Cochlear's evidence-led approach to developing breakthrough technology focused on all-day hearing and implant battery longevity, surgical familiarity, microphone performance and trust through experience and evidence SYDNEY, September 28, 2026--(BUSINESS WIRE)--Cochlear today announced the completion of recruitment for the worldwide pivotal trial program evaluating ful
- Published
- 28 Sep 2026 18:01
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Clinical TrialsHealthcareHearing TechnologyImplantable DevicesRegulation
—Unscored
Capital returnNot used in direction
Cochlear Ltd's Dividend Analysis
This article first appeared on GuruFocus. Evaluating the Sustainability of Cochlear Ltd's Upcoming Payout Cochlear Ltd (CHEOY) recently announced a total dividend of $0.47 per share, with the ex-dividend date set for 2026-09-22. This distribution includes a $0.47 per share cash dividend p…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article first appeared on GuruFocus. Evaluating the Sustainability of Cochlear Ltd's Upcoming Payout Cochlear Ltd (CHEOY) recently announced a total dividend of $0.47 per share, with the ex-dividend date set for 2026-09-22. This distribution includes a $0.47 per share cash dividend payable on 2026-11-03. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using data from GuruFocus, let's look into Cochlear Ltd's dividend performance and assess its sustainability. Understanding these metrics is crucial fo
- Published
- 22 Sep 2026 11:02
- News subject
- Capital return
- Why this score
- Capital returned
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Balance SheetDividend PaymentsDividendsEarningsEarnings GrowthGrowth
—Unscored
Capital returnNot used in direction
Do These 3 Checks Before Buying Cochlear Limited (ASX:COH) For Its Upcoming Dividend
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 18 Sep 2026 07:00
- News subject
- Capital return
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
57/100 tone
1.9% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 11 Sep 2026 10:15
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 32/100
- 30-day weight
- 1.9% of directional evidence · 27.8d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
Earlier company news
COH news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 44 older COH headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to COH, but the headline and available text are not mainly about Cochlear Limited. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of COH sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.